

AIDS Research and Human Retroviruses

AIDS Research and Human Retroviruses: <http://mc.manuscriptcentral.com/aidsresearch>

The evolving facets of bacterial vaginosis: implications for HIV transmission

Journal:	<i>AIDS Research and Human Retroviruses</i>
Manuscript ID	AID-2018-0304.R1
Manuscript Type:	Special Issue: Mucosal Immunology/the Microbiome
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>McKinnon, Lyle; University of Manitoba, Department of Medical Microbiology and Infectious Diseases; Centre for AIDS Programme of Research in South Africa (CAPRISA)</p> <p>Achilles, Sharon; University of Pittsburgh, Department of Obstetrics & Gynecology and Reproductive Sciences; Magee-Womens Research Institute</p> <p>Bradshaw, Catriona; Monash University, Central Clinical School; Melbourne Sexual Health Centre, Alfred Hospital</p> <p>Burgener, Adam; National HIV and Retrovirology Labs, Public Health Agency of Canada; University of Manitoba, Department of Obstetrics & Gynecology, and Medical Microbiology; Karolinska Institutet, Department of Medicine Solna</p> <p>Crucitti, Tania; Centre Pasteur du Cameroun</p> <p>Fredricks, David; Vaccine and Infectious Diseases, Fred Hutchinson Cancer Research Center; University of Washington, Department of Medicine</p> <p>Jaspan, Heather; Seattle Children's Research Institute and University of Washington; University of Cape Town</p> <p>Kaul, Rupert; University of Toronto, Department of Immunology; University of Toronto, Department of Medicine</p> <p>Kaushic, Charu; McMaster Immunology Research Centre, Michael G. DeGroote Centre of Learning and Discovery, MacMaster University; McMaster University, Department of Pathology and Molecular Medicine</p> <p>klatt, nichole; University of Miami, Department of Pediatrics</p> <p>Kwon, Douglas; Ragon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital; Harvard Medical School</p> <p>Marrazzo, Jeanne; University of Alabama at Birmingham, Division of Infectious Disease</p>

	Masson, Lindi; University of Cape Town, Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine (IDM); University of Cape Town, Centre for AIDS/HIV Program of Research In South Africa (CAPRISA) Centre of Excellence mcclelland, scott; University of Washington, Department of Medicine; University of Washington, Department of Epidemiology; University of Washington, Department of Global Health Ravel, Jacques; Institute for Genome Sciences and Department of Microbiology and Immunology, University of Maryland School of Medicine van de Wiggert, Janneke; Julius Center for Health Sciences and Primary Care, University Medical Center ; University of Liverpool, Institute of Infection and Global Health Vodstrcil, Lenka; Monash University, Central Clinical School; Melbourne Sexual Health Centre, Alfred Hospital Tachedjian, Gilda; Burnet Institute, Disease Elimination Program, Life Sciences Discipline; Monash University , Department of Microbiology; The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Department of Microbiology and Immunology; RMIT University, School of Science, College of Science, Engineering and Health
Keyword:	HIV, HIV transmission, Inflammation, Mucosal immunology, HIV prevention
Manuscript Keywords (Search Terms):	vaginal microbiota, bacterial vaginosis, HIV transmission, genital inflammation, HIV, female reproductive tract

SCHOLARONE™
Manuscripts

The evolving facets of bacterial vaginosis: implications for HIV transmission

Lyle R. McKinnon^{1,2,*}, Sharon L. Achilles^{3,4}, Catriona S. Bradshaw^{5,6},
Adam Burgener^{7,8,9}, Tania Crucitti¹⁰, David N Fredricks^{11,12}, Heather B Jaspan^{13,14},
Rupert Kaul^{15,16}, Charu Kaushic^{17,18}, Nichole Klatt¹⁹, Douglas S. Kwon^{20,21},
Jeanne M. Marrazzo²², Lindi Masson^{23,24}, R. Scott McClelland^{12,25,26}, Jacques Ravel²⁷,
Janneke H.H.M. van de Wijgert^{28,29}, Lenka A. Vodstrcil^{5,6}, Gilda Tachedjian^{30,31,32,33,*}

¹Department of Medical Microbiology and Infectious Diseases, University of Manitoba,
Winnipeg, Canada

²Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban,
South Africa

³University of Pittsburgh, Department Obstetrics, Gynecology and Reproductive
Sciences, Pittsburgh, PA USA

⁴Magee-Womens Research Institute, Pittsburgh, PA USA

⁵Central Clinical School, Monash University, Melbourne, Australia

⁶Melbourne Sexual Health Centre, Alfred Hospital, Carlton, Australia

⁷National HIV and Retrovirology Labs, Public Health Agency of Canada, Winnipeg,
Canada

⁸Department of Obstetrics & Gynecology, and Medical Microbiology, University of
Manitoba, Winnipeg, Canada

⁹Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden

¹⁰Centre Pasteur du Cameroun, Yaoundé ~~Yaounde~~, Cameroon

¹¹Vaccine and Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle
WA, USA

¹²Department of Medicine, University of Washington, Seattle, Washington, USA

¹³Seattle Children's Research Institute and University of Washington, Seattle WA

¹⁴University of Cape Town, South Africa

¹⁵Department of Immunology, University of Toronto, Toronto, Canada

¹⁶Department of Medicine, University of Toronto, Toronto, Canada

¹⁷McMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning
and Discovery, McMaster University, Hamilton, ON, Canada

¹⁸Department of Pathology and Molecular Medicine, McMaster University, Hamilton,
ON, Canada

¹⁹Department of Pediatrics, University of Miami, Miami, FL, USA

²⁰Ragon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital,
Cambridge, MA USA

²¹Harvard Medical School, Boston, MA USA

²²Division of Infectious Disease, University of Alabama at Birmingham, Birmingham, AL,
USA

²³Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine
(IDM), University of Cape Town, Cape Town, South Africa

²⁴Centre for AIDS/HIV Program of Research in South Africa (CAPRISA) Centre of
Excellence, University of Cape Town, Cape Town, South Africa

²⁵Department of Epidemiology, University of Washington, Seattle, Washington, USA

²⁶Department of Global Health, University of Washington, Seattle, Washington, USA

²⁷Institute for Genome Sciences and Department of Microbiology and Immunology,
University of Maryland School of Medicine, Baltimore MD, USA.

²⁸Julius Center for Health Sciences and Primary Care, University Medical Center
Utrecht, Utrecht, Netherlands

²⁹Institute of Infection and Global Health, University of Liverpool, Liverpool, UK

³⁰Disease Elimination Program, Life Sciences Discipline, Burnet Institute, Melbourne
Victoria, Australia

³¹Department of Microbiology, Monash University, Clayton Victoria, Australia

³²Department of Microbiology and Immunology at the Peter Doherty Institute for
Infection and Immunity, The University of Melbourne, Melbourne Victoria, Australia

³³School of Science, College of Science, Engineering and Health, RMIT University,
Melbourne Victoria, Australia

Corresponding authors.

Gilda Tachedjian,

Burnet Institute,

85 Commercial Rd, Melbourne Victoria 3004 Australia.

Email: gilda.tachedjian@burnet.edu.au

P +61 3 9282 2256

F +61 3 9282 2100

Lyle McKinnon

University of Manitoba

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Room 504, 745 Bannatyne Avenue,
Winnipeg, MB R3E 0J9, Canada

Email: lyle.mckinnon@umanitoba.ca

P +1 204 975 7708

F +1 204 789 3826

Running Title: Bacterial vaginosis and HIV transmission

Keywords: HIV, vaginal microbiota, bacterial vaginosis, HIV transmission, genital inflammation, female reproductive tract

Abstract

Bacterial vaginosis (BV) is a common yet poorly understood vaginal condition that has become a major focus of HIV transmission and immunology research. Varied terminologies are used by clinicians and researchers to describe microbial communities that reside in the female reproductive tract, which is driven in part by microbial genetic and metabolic complexity, evolving diagnostic and molecular techniques, and multidisciplinary perspectives of clinicians, epidemiologists, microbiologists, and immunologists who all appreciate the scientific importance of understanding mechanisms that underlie “BV”. This Perspectives article aims to clarify the varied terms used to describe the cervicovaginal microbiota and its “non-optimal” state, under the overarching term of BV. The ultimate goal is to move toward language standardization in future literature that facilitates a better understanding of the impact of BV on female reproductive tract immunology and risk of sexually transmitted infections including HIV.

Introduction

Bacteria are now recognized to play important immunological roles at all mucosal surfaces, and the female reproductive tract (FRT) is no exception.¹ The entirety of “optimal” microbial communities associated with a mucosal site (i.e. the microbiota) is an important contributor to the effectiveness of the host mucosal barrier against infection.² This is in contrast to “non-optimal” microbial communities that are associated with the disruption of important physiological roles of bacteria at the mucosa.¹ An example of non-optimal microbiota is bacterial vaginosis (BV) a common vaginal condition in women of reproductive-age associated with adverse urogenital and reproductive health outcomes including an increased risk of HIV acquisition.³⁻⁷ BV affects 29% of women in the United States and 52% of women in sub-Saharan Africa, where HIV is also highly prevalent.⁸

BV is commonly diagnosed by clinicians using Amsel’s criteria⁹, defined here as “Amsel-BV”, a ‘vaginal discharge syndrome’ where at least three out of four diagnostic criteria need to be met (Box 1). While women with BV can present with a vaginal discharge, BV is not typically associated with redness, swelling or pain seen with “overt” inflammation¹⁰, which is why it is referred to as “vaginosis” rather than “vaginitis”. However, BV is associated with “subclinical” genital inflammation, as determined by an increase in pro-inflammatory cytokines and chemokines¹⁰⁻¹⁶ associated with increased HIV risk.¹⁷⁻¹⁹ A second common method used to diagnose BV is by Nugent score, defined here as “Nugent-BV” (Box 1)²⁰. The Nugent score captures bacterial morphotypes on a Gram stain, differentiating *Lactobacillus*-dominated bacterial

communities from the presence of small Gram-variable rods (*Gardnerella vaginalis* morphotypes) and curved Gram-variable rods (*Mobiluncus* spp. morphotypes)⁵, which is an oversimplification of the actual ecology of BV.^{21,22}

Nugent scoring has been used widely, particularly in epidemiology research, to define BV in large cohort studies, correlating BV to a wide range of adverse health outcomes.^{18,19,23} A proportion of women with Nugent-BV are clinically asymptomatic (“asymptomatic BV”). Nugent-BV can be sustained or transient, the latter representing a temporary shift in the vaginal microbiota mediated by intrinsic (menses) or extrinsic (sex) factors²⁴, which may or may not be associated with increased HIV risk. Some women with Amsel-BV may also not present with symptoms; while this may be uncommon for women presenting to a clinic, population-based Amsel screening will identify asymptomatic Amsel-BV positive women. The presence of signs and symptoms of BV vary widely based on the perception of women and clinicians, complicating its diagnostic usefulness. Thus, BV that is diagnosed by either Amsel or Nugent methods can be further delineated as either “asymptomatic” or “symptomatic”.

While clinical manifestations of BV are important for patient care, it is now clear with advances in DNA sequencing technology that a broader range of non-optimal cervicovaginal microbiota have relevance for adverse sexual and reproductive health outcomes. CervicovVaginal microbiota are genetically and ecologically complex, diverse and dynamic.²⁴ This combined with its health implications has made it a “hot topic” for molecular microbiologists. Several immunological and clinical associations of various

cervicovaginal bacterial communities have now been characterized using molecular methods; these “non-optimal” microbiota broadly overlap with BV defined by other methods, but are distinct and we have termed these as “Molecular-BV” (Box 1). As subtle differences between methods come to light, “Molecular-BV” should be further subdivided into terms that incorporate the specific molecular method (Box 1). One common method for microbiota characterization in recent literature is deep sequencing of the 16S rRNA gene. This method has been termed as a “broad-range PCR” method that measures the relative abundance of bacteria taxa without pre-conceived knowledge of the bacteria that are present.²⁵⁻²⁸ We propose that “non-optimal” microbial communities defined by this technique be designated as “Seq-BV”, which would also incorporate whole genome shotgun-sequencing approaches. A second method is taxon-specific quantitative PCR (qPCR) that quantifies the absolute abundance of pre-determined taxa^{26,29}, while not including others. We propose that “non-optimal” taxa are designated as ‘qPCR-BV’. Metaproteomic analysis of cervicovaginal samples has also been employed to study the cervicovaginal environment, including bacterial composition, which has led to “optimal” and “non-optimal” bacterial community classifications, where the latter could be designated as Prot-BV.³⁰⁻³²

The concept of “Molecular-BV”, as defined currently in research settings, is intended to be an “overarching” term to describe non-optimal cervicovaginal microbiota characterized by molecular methods. This is not to suggest that it is not clinically relevant. An FDA approved molecular diagnostic test for BV is being used in the US.^{33,34} In addition, Molecular-BV has been associated with genital inflammation and/or adverse

sexual and reproductive health outcomes such as increased HIV risk^{17,29}, and therefore is prognostic for clinical outcomes. Understanding this distinction may enable better comparisons to studies where BV has been determined using Amsel's criteria or Nugent score.^{18,19}

Molecular-BV bacterial communities are depleted of *Lactobacillus* spp., with a high relative abundance or load of facultative and/or obligate anaerobes (see Box 1, and Table 1 for microbial communities typical of Molecular-BV).^{12,17,25-27} These communities are usually "highly diverse" (i.e. high species richness or polymicrobial) and show "evenness" (i.e. not dominated by particular species), although they can be dominated by the one species. Examples of Seq-BV include microbiota commonly referred to as cervicotypes 3 (CT3) and 4 (CT4), which proportionally are depleted of *Lactobacillus* spp. and predominately contain *Gardnerella vaginalis* or an increase in a mixture of diverse anaerobes comprising *Prevotella*, *Gardnerella*, *BVAB1*, *Sneathia* and *Megasphaera* spp., respectively.^{11,17} Examples of qPCR-BV include additional taxa shown to have a concentration-dependent association with genital inflammation and/or increased risk of HIV acquisition e.g. *Gemella asaccharolytica* and *Eggerthella* species type I.²⁹

Techniques used to define Molecular-BV have demonstrated that an even larger proportion of asymptomatic women may be at risk of sub-clinical cervicovaginal inflammation and increased risk of acquiring sexually transmitted infections (STI) including HIV.^{17,29} However, these overlapping yet distinct approaches for defining BV

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

have led to some confusion for researchers in the field. A patchwork of terms describing BV and cervicovaginal microbiota continues to evolve as studies employ increasingly complex molecular measurements to better capture aspects of the microbiota that go beyond clinical or microscopic criteria by using bacterial relative or absolute bacterial abundances. This Perspectives article attempts to capture the heterogeneous terminology generated from this multidisciplinary research effort geared at understanding the intricate relationships between “BV”, as defined by Amsel, Nugent and molecular methods, cervicovaginal inflammation, and the risk of HIV/STIs.

While here we focus on BV, it is important to note that there are additional forms of “non-optimal” cervicovaginal microbiota associated with vulvovaginal candidiasis (VVC) caused by *Candida* spp., and desquamative vaginitis or aerobic vaginitis caused by pathobionts *Proteobacteria*, *Streptococci*, *Staphylococci* or *Enterococci* spp.^{35,36} These microbes and STIs other than HIV are clinically relevant and are associated with genital inflammation that can increase HIV risk (Figure 1), and are therefore important when considering sources of inflammation in the cervicovaginal mucosa, but do not feature in the definitions of BV, which is the current focus of this Perspectives article.³⁵ An update on this topic is planned in a report on the 2018 Keystone Symposia on the Role of the Genital Tract Microbiome in Sexual and Reproductive Health.

Partial overlap between Amsel-BV, Nugent-BV, and Molecular-BV

Current evidence supports that only a minority of BV is symptomatic. Molecular-BV/Seq-BV, which categorizes microbiota into bacterial community types (Table 1), tends to

correlate with vaginal pH and not with other Amsel criteria, such as clue cells and whiff test.^{28,37} Similarly, although Seq-BV correlates with Nugent-BV (Figure 2), the overlap is incomplete.^{17,22,25} The majority of women who have an intermediate Nugent score (defined in Box 1) also have Seq-BV (e.g. CT3₊ and CT4₊ and CST-IV)^{11,17,22}, indicating an association with adverse health outcomes.¹⁷ We propose that data from primarily clinical (Amsel), microscopic (Nugent) and molecular evaluation of BV fit into an “iceberg” concept of a clinical/sub-clinical condition (Figure 2). Amsel-BV is at the top of the iceberg, usually capturing clinically apparent non-optimal vaginal microbiota, while both Nugent-BV and Molecular-BV include additional microbial states that can be sub-clinical (e.g. asymptomatic) but still clinically relevant for infection and/or health risk. It is worth noting that some Amsel positive diagnoses may not be Nugent positive due to either subjectivity of the Amsel criteria (e.g. vaginal discharge, odor) or perhaps differences in the ability of these tests to detect BV-associated with biofilm versus planktonic BV, although these cases are uncommon.

Non-optimal cervicovaginal microbiota, genital inflammation, and HIV acquisition risk

Meta-analyses clearly demonstrate that women with Nugent-BV and/or Amsel-BV have an increased risk of acquiring HIV.^{18,19} A meta-analysis by Atashili and colleagues (2008) of twenty-three studies including 30,739 women, reported a relative risk of 1.61 (95% confidence interval 1.21 - 2.13) for HIV acquisition in women with Nugent-BV. Subsequently, an individual patient meta-analysis by Low and colleagues (2011) reported that Nugent-BV, measured at the seronegative visit before HIV diagnosis, was

associated with an adjusted hazard ratio of 1.53 (95% CI 1.24-1.89) for HIV acquisition risk¹⁹. This study also demonstrated an elevated susceptibility to HIV (aHR 1.41, 95% CI 1.12-1.79) in women with intermediate Nugent scores¹⁹, suggesting that any Nugent score >3 may be a risk factor for HIV. On the basis of more recent molecular studies, a large proportion of these women would be expected to have Molecular-BV.^{11,17,22}

Nugent-BV has repeatedly been associated with genital inflammation; in particular, pro-inflammatory cytokines are typically up-regulated whereas chemokines show no association, are up-regulated (i.e. IL-8) or down-regulated.^{10,14-16} This cytokine-chemokine distinction is likely due to the observation that BV is microbiologically multifaceted, and specific combinations of bacterial species may result in different host responses.²⁸ The host response to the same bacterial communities could also vary between individuals, even though no studies have evaluated this specific question. In addition, some differences could be accounted for by methodological differences in sampling and measuring immune mediators in the genital tract.¹⁰

Molecular-BV has often been associated with both genital inflammation¹¹⁻¹³ and an increased risk of HIV acquisition.^{17,29} A prospective study in South Africa reported that young women colonised with a highly diverse community (CT4), had a 4.4-fold (95% CI: 1.17-16.61) increased risk of acquiring HIV compared to women with *L. crispatus*-dominant microbiota.¹⁷ Presence of the *G. vaginalis*-dominated (CT3) cervicotype demonstrated a trend towards elevated HIV risk although it did not reach statistical significance after adjusting for the presence of chlamydia.¹⁷ The *L. iners*-dominated

(CT2) cervicotype was not significantly associated with increased HIV risk.¹⁷ In this cohort, women with CT4 also had the greatest genital inflammation measured by levels of pro-inflammatory cytokines and chemokines, compared to women with *L. crispatus*-dominated microbiota, and followed by *G. vaginalis*-dominated and *L. iners*-dominated microbiota.¹¹ Another nested case-control study in African women showed that vaginal bacterial diversity and several BV-associated bacterial species, including *Parvimonas* species types 1 and 2, *Gemella asaccharolytica*, *Mycoplasma hominis*, *Leptotrichia/Sneathia*, *Eggerthella* species type 1, and *Megasphaera* species, were significantly associated with higher risk of HIV acquisition.²⁹

Several studies have demonstrated that elevated genital inflammation is associated with an increase in activated HIV target cells in the cervix^{11,17,38}, consistent with elevated HIV risk.¹⁷ However, not all studies have found an association between cervicovaginal bacterial communities and the frequency of CD4+ and CCR5+ activated or proliferating HIV target cells in the cervix^{12,39} suggesting differences between geographic or ethnic populations. Alternatively, there could be other mechanisms by which non-optimal cervicovaginal microbiota increase HIV risk, such as disruption of epithelial barrier integrity.^{30-32,38}

Effect Sizes for HIV risk determined by Nugent/Amsel-BV versus Molecular-BV

The effect sizes for Nugent-BV/Amsel-BV on HIV risk are typically smaller, i.e. 60% increased risk^{18,19} compared to the effect size from Seq-BV on HIV risk (i.e. >4-fold).^{17,28} However, the latter was only from two studies, with modest numbers of women

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

colonised with *L. crispatus*-dominated cervicovaginal microbiota, and needs to be confirmed.¹⁷ The large sample size (>30,000 individuals) evaluated in the BV meta-analysis could contribute to and explain the smaller effect sizes. The meta-analysis of Nugent-BV is also adjusted for potential confounders such as VVC and sexual behaviours, although these are incompletely controlled for in studies relying on Molecular-BV.^{17,29}

While Nugent and Amsel are useful tools for epidemiological and clinical studies they could be thought of as less sensitive, i.e., underestimating the types of microbiota that put a woman at risk for HIV, compared to molecular evaluation of cervicovaginal microbiota, at least in research settings (Figure 2). Nugent and molecular techniques can also detect brief episodes of “non-optimal” microbiota (e.g. during menses)²⁴ that may not cause significant genital inflammation and/or increase HIV risk and it is likely that more broadly, these communities may be dynamic, dependent upon a number of host and environmental factors (e.g. genital hygiene practices, sexual behavior, co-morbidities, etc.). Therefore the duration and frequency of “non-optimal” vaginal microbiota is likely a critical factor requiring the incorporation of frequent sampling in longitudinal studies to better define the HIV risk associated with Nugent-BV and Molecular-BV.

Not all *Lactobacillus* spp. are associated with reduced genital inflammation and protection against HIV acquisition

Lactobacillus spp.-dominated cervicovaginal microbiota, and particularly with *L. crispatus*, are associated with a lack of genital inflammation relative to other bacterial communities.^{11,12,16,17} In a cross-sectional study, women with *L. crispatus*-dominated microbiota were less likely to be HIV positive compared to women with vaginal microbiota either dominated by *L. iners* or depleted of *Lactobacillus* spp.⁴⁰ Furthermore, HIV was associated with a high bacterial load and abundance of strict and facultative anaerobes.⁴⁰ While this cross-sectional analysis could be due to reverse causation (i.e. HIV could cause microbiome differences), this observation is supported by a prospective study in South African adolescent girls where *L. crispatus*-dominated cervicovaginal microbiota, but not *L. iners*, was associated with a decreased risk of acquiring HIV.¹⁷ Additionally, *L. iners* was shown to be mildly inflammatory in *in vitro* co-cultures with vaginal epithelial cells.¹⁷ Thus while some *Lactobacillus* spp. are associated with decreased genital inflammation and HIV risk, not all *Lactobacillus* spp. are equally protective.

The difference in the ability of distinct *Lactobacillus* spp. to provide protection against HIV may be due to several factors that include their ability to produce lactic acid that is responsible for acidifying the vagina to a low pH.^{25,41-43} Lactic acid has been shown to have antimicrobial and immune modulatory properties.⁴⁴⁻⁴⁷ Modulation of inflammatory responses by *Lactobacillus* spp. may also be influenced by differences in cell wall properties between strains.^{48,49} Another factor is the apparent lower temporal stability of *L. iners*-dominated microbiota compared to *L. crispatus*-dominated microbiota. Indeed, when exposed to extrinsic and intrinsic factors, *L. iners*-dominated vaginal

microbiota often transition to bacterial communities lacking *Lactobacillus* spp. and comprising a wide array of strict and facultative anaerobes.^{24,50} It is important to note that there is likely to be strain differences among *Lactobacillus* spp. (including *L. crispatus*) with levels of genital inflammation (Chetwin et al., Sci Reports, in press) as well as *G. vaginalis* clades and HIV risk, which cannot be resolved by Nugent scoring or current 16S rRNA gene sequencing or qPCR approaches.

Asymptomatic Nugent-BV or Molecular-BV is still associated with genital inflammation

There is considerable controversy in the field regarding asymptomatic cases that lack *Lactobacillus* spp. as these appear disease free but may retain elevated risk of adverse health outcomes. Women who do not report any symptoms of BV but are positive for either Nugent- or Molecular-BV can still have “asymptomatic BV”^{35,51}, a state often associated with cervicovaginal microbiota dominated by *G. vaginalis* (e.g. CT3, Table 1)^{17,24} or are polymicrobial comprising facultative and/or obligate anerobes while lacking *Lactobacillus* spp. often described as community state type IV (CST-IV)²⁵, CT4¹⁷ or compositional subtype 1 (C1)^{12,52} (Table 1). However, BV, including asymptomatic Molecular-BV or Nugent-BV is often observed in African and Hispanic women^{17,25,28,51} suggesting that genetic, socioeconomic, cultural or behavioural factors might play a role alone or in combination. Further, report of symptoms is subjective and varies between women since these may be “normal” if a woman has had them her entire adult life. Yet her risk of HIV infection and other sexual and reproductive health outcomes may still be elevated due to asymptomatic Nugent-BV or Molecular-BV. In Gosmann et al., the

majority of women who acquired HIV were asymptomatic and negative for Nugent-BV, despite having evidence of Molecular-BV.¹⁷ Thus, reliance on symptoms alone is not recommended for assessing increased risk for HIV. In the future, if methods to positively and effectively alter the microbiota are achieved, screening asymptomatic women in clinical practice may also be appropriate.

Terminology, definitions and recommendations

We list terminologies often used in the cervicovaginal microbiome field and provide definitions as a guide for investigators to promote precision and consistency (Box 1, Tables 1 and 2). We also propose the following recommendations for the field to consider.

1. There is a preferred consensus developing around the term “optimal” to describe cervicovaginal microbiota often associated with favourable health outcomes and characterized by a lack of symptoms, dominance of non-*L. iners* *Lactobacillus* spp. and a lack of genital inflammation. “Non-optimal” is preferred to describe microbiota-associated with adverse sexual and reproductive health outcomes, including increased HIV acquisition risk (Figure 1).
2. Avoid use of the terms “dysbiotic” or “abnormal” microbiota, since both of these terms imply divergence from a normal state that might not exist for all women. For women with asymptomatic BV and low levels of genital inflammation, their

microbial community might represent their “normal” microbial state and these terms may inappropriately stigmatize these women.

- 3. We suggest that descriptive terms to describe the microbiota (i.e. in recommendations 1 and 2) should be tested for acceptability with women in qualitative studies such that terminology is friendly to women who may be likely to benefit from the development of approaches to reverse the consequences of Molecular-BV.
- 4. We propose new terminology that specifies the method used to diagnose BV i.e. Amsel-BV (based on Amsel criteria), Nugent-BV (defined by Nugent score), Molecular-BV (based on molecular methods), with subcategories defining the molecular technique employed i.e. Seq-BV or qPCR-BV (Box 1). Appropriate abbreviations could also be used for “non-optimal” microbiota identified through new and emerging technologies including metagenomics, transcriptomics, metabolomics and metaproteomics.
- 5. Amsel-BV, Nugent-BV and Molecular-BV can be further delineated into symptomatic or asymptomatic. Studies based on stratification of symptomatic BV is not recommended, given that “symptoms” can be subjective and do not fully capture the cervicovaginal microbiota associated with important health outcomes.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
6. Not all “non-optimal” microbiota are “highly diverse” i.e. *G. vaginalis*-dominated microbiota (e.g. CT3, CST-IVB)^{11,17,24 25}, which has also been referred to as “low diversity anaerobic dysbiosis” as distinct from “high diversity anaerobic dysbiosis” such as CT4 and CST-IVC.³⁵ However, it is important to be precise when using the term “diverse” to describe microbiota. The use of the term “diverse” can be ambiguous with respect to 16S rRNA gene sequencing data. It is often used to describe communities such as CT4 and CST-IVC that have “species richness” i.e. many different species in a microbial ecosystem and “evenness” i.e. not dominated by particular species. However, it is possible that a community dominated by *L. crispatus* (e.g. CT1, CST-I, C2) can have high within community intraspecies diversity (Ravel unpublished). In addition, “*L. crispatus*-dominated” microbiota could also be diverse, as a result of diversity due to very low abundance taxa representing less than 1% of the community (i.e. an uneven community).
7. When describing *Lactobacillus* spp. as “optimal” or “beneficial”, specify the *Lactobacillus* species. Not all *Lactobacillus* spp. or strains make ‘optimal’ cervicovaginal microbiota. Current data indicates that most strains of *L. iners* are less stable²⁴, associated with increased genital inflammation¹⁷, and encodes factors that may be harmful to the vaginal mucosa.^{53,54}
8. We propose terminology that describes cervicovaginal microbiota associated with genital inflammation (MAGI) and microbiota associated with HIV acquisition

(MAHA). While the focus of this Perspectives article is on BV, these terms would also encompass STIs, pathobionts and VVC. Use of these terminologies, including “susceptible” for HIV requires that there is evidence that the cervicovaginal microbiota increases genital inflammation (MAGI) and/or HIV risk (MAHA). These are overlapping but distinct microbiota-associated phenotypes (Figure 1).

- 9. There is a need for standardisation of methodology and terminology for characterising bacterial communities by 16S rRNA gene sequencing (e.g CSTs, CTs, Cs) defined by clustering analysis preferably compared to a reference database comprising a large number of cervicovaginal microbiota to avoid collapsing of distinct clusters due to low numbers of samples being analysed. Such a database (data from 12,000 samples) has been established by Jacques Ravel, which will be made available for use (unpublished). Other areas of standardisation are sample site (e.g. vaginal, cervical, lavage), sample processing and the use of primers directed to the same 16S rRNA gene region for amplification.
- 10. More frequent sampling of cervicovaginal microbiota is recommended when determining the association of a cervicovaginal microbiota states with adverse health outcomes as well as more rigorous controlling of confounders that are associated with genital inflammation including STIs and VVC.

12. Advance scientific knowledge into the mechanisms that underpin epidemiological associations observed with distinct microbial communities and HIV risk that is critical for driving the development of viable treatment and prevention modalities to promote an optimal microbiota and prevent HIV. Develop better tissue and animal models that recapitulate the FRT and can be colonised with women's cervicovaginal microbiota and infected with HIV.

Conclusions.

Regardless of how it is defined, it is clear that BV is a topic of growing interest and importance for sexual and reproductive health in women. To facilitate making sense of this expanding research effort, we propose to use standardized definitions that “best capture genital inflammation and/or HIV/STI risk”. On this basis molecular methods for characterizing the cervicovaginal microbiota are anticipated to replace both Nugent and Amsel as a BV gold standard. This does not imply that Nugent and Amsel no longer have a role in assessing clinical BV. In clinical practice, Amsel will remain useful for diagnosing symptomatic BV; however, new sensitive and specific molecular diagnostic tests are becoming available such as the FDA approved BD MAX vaginal panel.^{33 34} Many properly trained sites may opt to continue use of Nugent-BV due to cost or logistical reasons since there is a plethora of data published on Nugent-BV and it is known to capture a proportion of individuals colonised with abundance of non-*Lactobacillus*-dominated bacterial communities with high specificity. However, to really understand the role of the non-optimal cervicovaginal microbiota in HIV and

inflammation, it will be necessary to employ a range of “omic” techniques including metagenomics (next generation DNA sequencing of whole bacteria, not only the 16S rRNA gene), transcriptomics, proteomics, and metabolomics in conjunction with immunological measurements. Use of these techniques will be necessary to advance our knowledge of BV and conditions that promote BV so that better treatments can be developed and to stop the cycle of frequent recurrence that is commonplace with current treatments.

Acknowledgements

A.D.B. and L.R.M. are funded by the Canadian Institutes of Health Research (CIHR) grant TMI-138658. L.R.M is supported by a CIHR New Investigator Award and A.D.B by the CIHR New Investigator in HIV Award NIH-15404. R. K. is funded by CIHR grant PJT-156123. C. K. ~~is was~~ funded by an Ontario HIV Treatment Network (OHTN) Applied HIV Chair award and operating grants and an HIV Team grant from CIHR. J. R. was supported by the National Institute for Allergy and Infectious Diseases of the National Institutes of Health under award number U19AI084044. G. T. is ~~funded~~^{supported} by the National Health and Medical Research Council of Australia (NHMRC) Senior Research Fellowship GNT1117748. G. T. gratefully acknowledges the contribution of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.

Author Disclosure Statement

D.N.F. declares intellectual property around the molecular diagnosis of BV and receives royalty from BD. J.M.M. is a consultant for Biofire, receives research supplies from Merck and Toltec Pharmaceuticals, and serves on the DSMB for Gilead. G. T. is a co-inventor on patent application AU201501042 and United States Patent No: US 9,801,839 B2 claiming the anti-inflammatory effects of lactic acid. The remaining authors have no competing financial interests to declare

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Libertucci J, Young VB. The role of the microbiota in infectious diseases. *Nat Microbiol* 2019;4:35-45.
2. Burgener A, McGowan I, Klatt NR. HIV and mucosal barrier interactions: consequences for transmission and pathogenesis. *Curr Opin Immunol* 2015;36:22-30.
3. Ma B, Forney LJ, Ravel J. Vaginal microbiome: rethinking health and disease. *Annu Rev Microbiol* 2012;66:371-389.
4. Marrazzo JM, Martin DH, Watts DH, et al. Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. *Sex Transm Dis* 2010;37:732-744.
5. Martin DH, Marrazzo JM. The Vaginal Microbiome: Current Understanding and Future Directions. *J Infect Dis* 2016;214 Suppl 1:S36-41.
6. Aldunate M, Srbínovski D, Hearps AC, et al. Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal

- microbiota associated with eubiosis and bacterial vaginosis. *Front Physiol* 2015;6:164.
7. Cohen CR, Lingappa JR, Baeten JM, *et al.* Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. *PLoS Med* 2012;9:e1001251.
 8. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. *Am J Obstet Gynecol* 2013;209:505-523.
 9. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. *Am J Med* 1983;74:14-22.
 10. Mitchell C, Marrazzo J. Bacterial vaginosis and the cervicovaginal immune response. *Am J Reprod Immunol* 2014;71:555-563.
 11. Anahtar MN, Byrne EH, Doherty KE, *et al.* Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. *Immunity* 2015;42:965-976.
 12. Lennard K, Dabee S, Barnabas SL, *et al.* Microbial composition predicts genital tract inflammation and persistent bacterial vaginosis in South African adolescent females. *Infect Immun* 2018;86:e00410-17
 13. Gautam R, Borgdorff H, Jespers V, *et al.* Correlates of the molecular vaginal microbiota composition of African women. *BMC Infect Dis* 2015;15:86.
 14. Masson L, Mlisana K, Little F, *et al.* Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. *Sex Transm Infect* 2014;90:580-587.

15. Deese J, Masson L, Miller W, et al. Injectable progestin-only contraception is associated with increased levels of pro-inflammatory cytokines in the female genital tract. *Am J Reprod Immunol* 2015;74:357-367.

16. Kyongo JK, Crucitti T, Menten J, et al. Cross-sectional analysis of selected genital tract immunological markers and molecular vaginal microbiota in sub-Saharan African women, with relevance to HIV risk and prevention. *Clin Vaccine Immunol* 2015;22:526-538.

17. Gosmann C, Anahtar MN, Handley SA, et al. Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. *Immunity* 2017;46:29-37.

18. Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. *AIDS* 2008;22:1493-1501.

19. Low N, Chersich MF, Schmidlin K, et al. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. *PLoS Med* 2011;8:e1000416.

20. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. *J Clin Microbiol* 1991;29:297-301.

21. Srinivasan S, Morgan MT, Liu C, et al. More than meets the eye: associations of vaginal bacteria with gram stain morphotypes using molecular phylogenetic analysis. *PLoS One* 2013;8:e78633.

22. Wessels JM, Lajoie J, Vitali D, *et al.* Association of high-risk sexual behaviour with diversity of the vaginal microbiota and abundance of *Lactobacillus*. *PLoS One* 2017;12:e0187612.
23. Kroon SJ, Ravel J, Huston WM. Cervicovaginal microbiota, women's health, and reproductive outcomes. *Fertil Steril* 2018;110:327-336.
24. Gajer P, Brotman RM, Bai G, *et al.* Temporal dynamics of the human vaginal microbiota. *Sci Transl Med* 2012;4:132ra152.
25. Ravel J, Gajer P, Abdo Z, *et al.* Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci U S A* 2011;108 Suppl 1:4680-4687.
26. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. *N Engl J Med* 2005;353:1899-1911.
27. Fettweis JM, Serrano MG, Sheth NU, *et al.* Species-level classification of the vaginal microbiome. *BMC Genomics* 2012;13 Suppl 8:S17.
28. Srinivasan S, Hoffman NG, Morgan MT, *et al.* Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. *PLoS One* 2012;7:e37818.
29. McClelland RS, Lingappa JR, Srinivasan S, *et al.* Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study. *Lancet Infect Dis* 2018;18:554-564.
30. Zevin AS, Xie IY, Birse K, *et al.* Microbiome composition and function drives wound-healing impairment in the female genital tract. *PLoS Pathog* 2016;12:e1005889.

31. Klatt NR, Cheu R, Birse K, *et al.* Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. *Science* 2017;356:938-945.
32. Borgdorff H, Gautam R, Armstrong SD, *et al.* Cervicovaginal microbiome dysbiosis is associated with proteome changes related to alterations of the cervicovaginal mucosal barrier. *Mucosal Immunol* 2016;9:621-633.
33. Gaydos CA, Beqaj S, Schwebke JR, *et al.* Clinical validation of a test for the diagnosis of vaginitis. *Obstet Gynecol* 2017;130:181-189.
34. Schwebke JR, Gaydos CA, Nyirjesy P, Paradis S, Kodsí S, Cooper CK. Diagnostic performance of a molecular test versus clinician assessment of vaginitis. *J Clin Microbiol* 2018;56:e00252-18
35. van de Wijgert J. The vaginal microbiome and sexually transmitted infections are interlinked: Consequences for treatment and prevention. *PLoS Med* 2017;14:e1002478.
36. Donders GG, Ruban K, Bellen G. Selecting anti-microbial treatment of aerobic vaginitis. *Curr Infect Dis Rep* 2015;17:477.
37. van de Wijgert JH, Borgdorff H, Verhelst R, *et al.* The vaginal microbiota: what have we learned after a decade of molecular characterization? *PLoS One* 2014;9:e105998.
38. Arnold KB, Burgener A, Birse K, *et al.* Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. *Mucosal Immunol* 2016;9:194-205.

39. Shannon B, Gajer P, Yi TJ, *et al.* Distinct effects of the cervicovaginal microbiota and herpes simplex type 2 infection on female genital tract immunology. *J Infect Dis* 2017;215:1366-1375.
40. Borgdorff H, Tsivtsivadze E, Verhelst R, *et al.* Lactobacillus-dominated cervicovaginal microbiota associated with reduced HIV/STI prevalence and genital HIV viral load in African women. *ISME J* 2014;8:1781-1793.
41. O'Hanlon DE, Moench TR, Cone RA. Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. *PLoS One* 2013;8:e80074.
42. Witkin SS, Mendes-Soares H, Linhares IM, Jayaram A, Ledger WJ, Forney LJ. Influence of vaginal bacteria and D- and L-lactic acid isomers on vaginal extracellular matrix metalloproteinase inducer: implications for protection against upper genital tract infections. *MBio* 2013;4:e00460-13
43. Tyssen D, Wang YY, Hayward JA, *et al.* Anti-HIV-1 activity of lactic acid in human cervicovaginal fluid. *mSphere* 2018;3:e00055-18.
44. Tachedjian G, Aldunate M, Bradshaw CS, Cone RA. The role of lactic acid production by probiotic Lactobacillus species in vaginal health. *Res Microbiol* 2017;168:782-792.
45. Aldunate M, Tyssen D, Johnson A, *et al.* Vaginal concentrations of lactic acid potentially inactivate HIV. *J Antimicrob Chemother* 2013;68:2015-2025.
46. Tachedjian G, O'Hanlon DE, Ravel J. The implausible "in vivo" role of hydrogen peroxide as an antimicrobial factor produced by vaginal microbiota. *Microbiome* 2018;6:29.

47. Hearps AC, Tyssen D, Srbinovski D, et al. Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. *Mucosal Immunol* 2017;10:1480-1490.

48. Chapot-Chartier MP, Kulakauskas S. Cell wall structure and function in lactic acid bacteria. *Microb Cell Fact* 2014;13 Suppl 1:S9.

49. Macho Fernandez E, Valenti V, Rockel C, et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. *Gut* 2011;60:1050-1059.

50. Ravel J, Brotman RM, Gajer P, et al. Daily temporal dynamics of vaginal microbiota before, during and after episodes of bacterial vaginosis. *Microbiome* 2013;1:29.

51. Masson L, Barnabas S, Deese J, et al. Inflammatory cytokine biomarkers of asymptomatic sexually transmitted infections and vaginal dysbiosis: a multicentre validation study. *Sex Transm Infect* 2018.

52. Balle C, Lennard K, Dabee S, et al. Endocervical and vaginal microbiota in South African adolescents with asymptomatic Chlamydia trachomatis infection. *Sci Rep* 2018;8:11109.

53. Macklaim JM, Fernandes AD, Di Bella JM, Hammond JA, Reid G, Gloor GB. Comparative meta-RNA-seq of the vaginal microbiota and differential expression by *Lactobacillus iners* in health and dysbiosis. *Microbiome* 2013;1:12.

54. Petrova MI, Reid G, Vaneechoutte M, Lebeer S. *Lactobacillus iners*: Friend or Foe? Trends Microbiol 2017;25:182-191.

Figure 1. Microbial causes of genital inflammation and/or altered HIV susceptibility.

Each microbial class can cause inflammation independently or in combination with other microbes that may also be present in the same women. Strategies to mitigate as many of these causes as possible may be key to achieving the optimal FRT mucosa associated with positive health outcomes including protection against HIV infection. Optimal, cervicovaginal microbiota associated with no vaginal symptoms, lack of genital inflammation and decreased HIV risk; non-optimal, cervicovaginal microbiota associated with vaginal symptoms and/or genital inflammation and/or increased HIV risk; MAHA, microbiota associated with HIV acquisition; GI, genital inflammation; MAGI, microbiota associated with genital inflammation; BV, bacterial vaginosis; STIs, sexually transmitted infections; pathobionts, a symbiotic organism under normal circumstances that can become pathogenic e.g. *Proteobacteria*, *Streptococci*, *Staphylococci* or *Enterococci*.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

spp.; VVC, vulvovaginal candidiasis; ?, *Lactobacillus* spp. (e.g. *L. iners*) or strains that may not be optimal.

Figure 2. The “clinical iceberg” concept of adverse health outcomes, applied to BV. With better molecular methods we now appreciate that clinically evident BV, as diagnosed by a technique like Amsel’s criteria (Amsel-BV), does not capture a high proportion of women diagnosed with BV by Nugent (Nugent-BV) or by using molecular methods (Molecular-BV) that contributes to adverse sexual and reproductive health outcomes including increased HIV risk. Not all Amsel-BV positive samples are Nugent-BV or Molecular-BV positive with this lack of overlap denoted by the red vertical line.

Table 1. Classification of Cervicovaginal Bacterial Communities Determined by 16S rRNA Gene Sequencing

Abbreviation	Definition	Molecular-BV (Seq-BV)
CST-I	<i>L. crispatus</i> dominated	NO
CST-II	<i>L. gasseri</i> dominated	NO
CST-III	<i>L. iners</i> dominated	NO
CST-IVA	Modest <i>Lactobacillus</i> spp. higher relative abundance of facultative and/or obligate anaerobes, <i>BVAB1</i> and <i>G. vaginalis</i>	YES
CST-IVB	Modest <i>Lactobacillus</i> spp. higher relative abundance of facultative and/or obligate anaerobes, <i>G. vaginalis</i> and <i>Atopobium vaginae</i>	YES
CST-IVC	Lacking <i>Lactobacillus</i> spp. and more even in anaerobe composition (i.e. no bacteria dominates) comprising <i>Prevotella</i> among others, as well as <i>Anaerococcus</i> , <i>Finegoldia</i> , <i>Corynebacterium</i> , <i>Peptoniphilus</i> , <i>Megasphaera</i> , <i>Gemella</i> spp.	YES
CST-V	<i>L. jensenii</i> dominated	NO
CT1	<i>L. crispatus</i> dominated	NO
CT2	<i>L. iners</i> dominated	NO
CT3	Depleted of <i>Lactobacillus</i> spp. and <i>G. vaginalis</i> -predominated	YES
CT4	Depleted <i>Lactobacillus</i> spp. and polymicrobial with a higher relative abundance of facultative and/or obligate anaerobes comprising <i>Prevotella</i> , <i>Gardnerella</i> , <i>BVAB1</i> , <i>Sneathia</i> and <i>Megasphaera</i> spp.	YES
C1	Depleted of <i>Lactobacillus</i> spp. and polymicrobial with a higher relative abundance of facultative and/or obligate anaerobes	YES
C2	<i>L. crispatus</i> dominated	NO
C3	<i>L. iners</i> dominated	NO

Molecular-BV, bacterial vaginosis determined by characterising vaginal or cervical samples using molecular methods; Seq-BV, BV as determined by 16S rRNA gene sequencing; CST, community state type^{24,25}; CT, cervicotype^{11,17}; C, compositional subtype^{12,52}

Table 2. Descriptive terms for cerviovaginal microbiota

Terms for Optimal Microbiota		Definition
Optimal		Microbiota associated with no vaginal symptoms, lack of genital inflammation and favourable sexual and reproductive health outcomes, including decrease risk of HIV acquisition
Eubiosis		Microbiota that are “optimal”
Healthy		Microbiota that are “optimal”
Normal		Often used to describe “optimal” microbiota; less preferred terminology since “normal” is difficult to define
Lactobacillus dominant (LD)		Microbiota dominated by <i>Lactobacillus</i> spp. usually determined by 16S rRNA gene sequencing
Beneficial lactobacilli		Optimal <i>Lactobacillus</i> spp , often used to distinguish <i>L. crispatus</i> (optimal) from <i>L. iners</i>
Protective		Microbiota that protects against adverse health outcomes such as HIV. Evidence of in vivo protection is required
Non-BV		Microbiota composed of bacteria not consistent with bacterial vaginosis
Microflora		Outdated terminology that should not be used to describe microbiota. Suggests that microbiota are composed of plants rather than bacteria, fungi, viruses, archea, protists.
Terms for Non-Optimal Microbiota		
Non-optimal		Microbiota associated with vaginal symptoms, and/or genital inflammation and/or adverse sexual and reproductive health outcomes including increased risk of HIV acquisition
Dysbiosis		Imbalance in the microbiota or impaired microbiota or “non-optimal” microbiota. Avoid using this terminology for women with asymptomatic BV and low levels of genital inflammation as their microbiota might represent their “normal” state and may inappropriately be stigmatizing
Low diversity anaerobic dysbiosis		<i>G. vaginalis</i> or <i>A. vaginae</i> dominated microbiota associated with adverse sexual and reproductive health outcomes
High diversity anaerobic dysbiosis		Polymicrobial community depleted of <i>Lactobacillus</i> spp. associated with adverse sexual and reproductive health outcomes

Harmful	Less preferred terminology for microbiota associated with vaginal symptoms, genital inflammation, and/or an increased risk of adverse sexual and reproductive health outcomes
Non-Lactobacillus dominant (Non-LD)	Non-lactobacillus spp. dominated bacterial community
Polymicrobial	Multiple bacterial species usually depleted of <i>Lactobacillus</i> spp. with an increase in obligate and/or facultative anaerobes.
Diverse	Used to describe microbial communities comprising multiple bacterial species in the ecosystem. Needs to be defined since meaning can be ambiguous with respect to 16S rRNA gene sequencing.
Susceptible	Microbiota associated with increased risk of HIV and other STIs or adverse reproductive health outcomes. Requires evidence to link microbiota to adverse health outcomes.
MAGI	Microbiome associated with genital inflammation. This term can also encompass STIs and other microbes associated with genital inflammation including <i>Candida</i> spp. Requires evidence linking microbiota to genital inflammation
MAHA	Microbiome associated with HIV acquisition. This term can also encompass STIs and other microbes associated with genital inflammation including <i>Candida</i> spp. Requires evidence linking microbiota to increased HIV risk
Pathobionts	Symbiotic organism under normal circumstances that becomes pathogenic e.g. <i>Proteobacteria</i> , <i>Streptococci</i> , <i>Staphylococci</i> or <i>Enterococci</i> spp.

Box 1. Proposed definitions for bacterial vaginosis (BV) based on traditional methods for BV diagnosis (Amsel and Nugent) and molecular techniques.

Figure 1. Microbial causes of genital inflammation and/or altered HIV susceptibility.

Each microbial class can cause inflammation independently or in combination with other microorganisms that may also be present in the same women. Strategies to mitigate as many of these causes as possible may be key to achieving the optimal FRT mucosa associated with positive health outcomes including protection against HIV infection.

Optimal, cervicovaginal microbiota associated with no vaginal symptoms, lack of genital inflammation and decreased HIV risk; non-optimal, cervicovaginal microbiota associated with vaginal symptoms and/or genital inflammation and/or increased HIV risk; MAHA, microbiota associated with HIV acquisition; GI, genital inflammation; MAGI, microbiota associated with genital inflammation; BV, bacterial vaginosis; STIs, sexually transmitted infections; pathobionts, a symbiotic organism under normal circumstances that can become pathogenic e.g. *Proteobacteria*, *Streptococci*, *Staphylococci* or *Enterococci* spp.; VVC, vulvovaginal candidiasis; ?, *Lactobacillus* spp. (e.g. *L. iners*) or strains that may not be optimal.


Figure 2. The “clinical iceberg” concept of adverse health outcomes, applied to BV.

With better molecular methods we now appreciate that clinically evident BV, as diagnosed by a technique like Amsel’s criteria (Amsel-BV), does not capture a high proportion of women diagnosed with BV by Nugent (Nugent-BV) or by using molecular methods (Molecular-BV) that contributes to adverse sexual and reproductive health outcomes including increased HIV risk. Not all Amsel-BV positive samples are Nugent-BV or Molecular-BV positive with this lack of overlap denoted by the red vertical line.

Amsel-BV	<p>BV meets at least 3 of 4 Amsel’s criteria:</p> <ul style="list-style-type: none">• Abnormal discharge• pH>4.5• Clue cells• Fish odor <p>Symptomatic or Asymptomatic</p>
Nugent-BV	<p>BV diagnosed by Gram Stain:</p> <ul style="list-style-type: none">• Nugent score 7 – 10 (Nugent-BV)• Nugent score 4 - 6 (Intermediate-BV) <p>Nugent score 0 – 3 (Non BV) <i>Lactobacillus</i>-dominated^</p> <p>Symptomatic or Asymptomatic</p>
Molecular-BV	<p>General term for “non-optimal” bacterial communities depleted of lactobacilli with abundant anaerobes* characterized by molecular techniques</p>
Seq-BV	<ul style="list-style-type: none">• 16S rRNA gene sequencing or broad-range PCR. Shotgun sequencing approaches <p>High relative abundance of anaerobes* depleted of <i>Lactobacillus</i> spp. associated with increased genital inflammation and/or HIV risk#</p>
qPCR-BV	<ul style="list-style-type: none">• Taxon specific quantitative PCR <p>“Non-optimal” taxa demonstrating concentration dependent associations with increased genital inflammation and/or odds of HIV risk</p> <p>Symptomatic or Asymptomatic</p>
<p>^Depends on the population studied²² *Polymicrobial/diverse or <i>G. vaginalis</i> predominated #May also be associated with other adverse sexual as well as reproductive health outcomes</p>	

Box 1. Proposed definitions for bacterial vaginosis (BV) based on traditional methods for BV diagnosis (Amsel and Nugent) and molecular techniques

160x253mm (300 x 300 DPI)



Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801




Figure 2. The “clinical iceberg” concept of adverse health outcomes, applied to BV.
190x208mm (300 x 300 DPI)